

Robert H Mach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6054181/publications.pdf>

Version: 2024-02-01

259
papers

12,605
citations

28274

55
h-index

34986

98
g-index

281
all docs

281
docs citations

281
times ranked

12764
citing authors

#	ARTICLE	IF	CITATIONS
1	Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1 Targeted ¹⁸ F-Fluorothantrate PET Images of Ovarian Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 44-50.	5.0	11
2	The Development of ¹⁸ F Fluorothantrate: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1. <i>Radiology Imaging Cancer</i> , 2022, 4, e210070.	1.6	3
3	Screening of ² Receptor Ligands and <i>In Vivo</i> Evaluation of ¹¹ C-Labeled 6,7-Dimethoxy-2-[4-(4-methoxyphenyl)butan-2-yl]-1,2,3,4-tetrahydroisoquinoline for Potential Use as a ² Receptor Brain PET Tracer. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6261-6272.	6.4	10
4	Inflammation in Experimental Models of α -Synucleinopathies. <i>Movement Disorders</i> , 2021, 36, 37-49.	3.9	24
5	Synthesis, binding, and functional properties of tetrahydroisoquinolino-2-alkyl phenones as selective ² R/TMEM97 ligands. <i>European Journal of Medicinal Chemistry</i> , 2021, 209, 112906.	5.5	8
6	PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of Glioblastoma. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 344-351.	4.9	16
7	ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells. <i>Nature Cell Biology</i> , 2021, 23, 160-171.	10.3	85
8	Molecular Imaging: PARP-1 and Beyond. <i>Journal of Nuclear Medicine</i> , 2021, 62, 765-770.	5.0	11
9	Highlight selection of radiochemistry and radiopharmacy developments by editorial board. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 13.	3.9	1
10	Evaluation of a Low-Toxicity PARP Inhibitor as a Neuroprotective Agent for Parkinson's Disease. <i>Molecular Neurobiology</i> , 2021, 58, 3641-3652.	4.0	10
11	Interaction of Ligands for PET with the Dopamine D3 Receptor: In Silico and In Vitro Methods. <i>Biomolecules</i> , 2021, 11, 529.	4.0	6
12	Evaluation of Substituted N-Phenylpiperazine Analogs as D3 vs. D2 Dopamine Receptor Subtype Selective Ligands. <i>Molecules</i> , 2021, 26, 3182.	3.8	6
13	Poly (ADP-ribose) Interacts With Phosphorylated α -Synuclein in Post Mortem PD Samples. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 704041.	3.4	14
14	PARKinson's: From cellular mechanisms to potential therapeutics. , 2021, , 107968.		4
15	Improved production of ⁷⁶ Br, ⁷⁷ Br and ^{80m} Br via CoSe cyclotron targets and vertical dry distillation. <i>Nuclear Medicine and Biology</i> , 2020, 80-81, 32-36.	0.6	15
16	PARP-1 Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma. <i>Journal of Nuclear Medicine</i> , 2020, 61, 850-856.	5.0	30
17	Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene. <i>Molecular Therapy</i> , 2020, 28, 42-51.	8.2	70
18	Breast Cancer ¹⁸ F-ISO-1 Uptake as a Marker of Proliferation Status. <i>Journal of Nuclear Medicine</i> , 2020, 61, 665-670.	5.0	24

#	ARTICLE	IF	CITATIONS
19	Kinetics of Nanoparticle Radiolabeling of Metalloporphyrin with ⁶⁴ Cu for Positron Emission Tomography (PET) Imaging. <i>Industrial & Engineering Chemistry Research</i> , 2020, 59, 19126-19132.	3.7	3
20	The Biological Function of Sigma-2 Receptor/TMEM97 and Its Utility in PET Imaging Studies in Cancer. <i>Cancers</i> , 2020, 12, 1877.	3.7	30
21	Identification of a nanomolar affinity β -synuclein fibril imaging probe by ultra-high throughput <i>in silico</i> screening. <i>Chemical Science</i> , 2020, 11, 12746-12754.	7.4	30
22	Ligand with Two Modes of Interaction with the Dopamine D ₂ Receptor—An Induced-Fit Mechanism of Insurmountable Antagonism. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3130-3143.	3.5	8
23	PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response. <i>Molecules</i> , 2020, 25, 6029.	3.8	20
24	The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of A β 242 and Its Protein Aggregates. <i>Molecular Neurobiology</i> , 2020, 57, 3803-3813.	4.0	49
25	Synthesis and characterization of high affinity fluorogenic β -synuclein probes. <i>Chemical Communications</i> , 2020, 56, 3567-3570.	4.1	24
26	Positron Emission Tomography Imaging of Poly β -(Adenosine Diphosphate β -Ribose) Polymerase 1 Expression in Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 921.	7.1	26
27	Translocator protein in late stage Alzheimer's disease and Dementia with Lewy bodies brains. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1423-1434.	3.7	22
28	Design, synthesis, and evaluation of N-(4-(4-phenyl piperazin-1-yl)butyl)-4-(thiophen-3-yl)benzamides as selective dopamine D3 receptor ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2690-2694.	2.2	17
29	Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 7.	3.9	9
30	Automated synthesis of [11C]L-glutamine on Synthra HCN plus synthesis module. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 5.	3.9	5
31	Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. <i>Clinical and Translational Imaging</i> , 2019, 7, 61-63.	2.1	3
32	Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [18F]FLT and [18F]ISO-1 PET/CT. <i>Clinical Cancer Research</i> , 2019, 25, 3063-3073.	7.0	27
33	TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death. <i>Cell Death Discovery</i> , 2019, 5, 58.	4.7	43
34	Correlation analysis of [18F]ROStrace using <i>ex vivo</i> autoradiography and dihydroethidium fluorescent imaging in lipopolysaccharide-treated animals. <i>Biochemical and Biophysical Research Communications</i> , 2019, 516, 397-401.	2.1	6
35	Status of the β -consensus nomenclature rules in radiopharmaceutical sciences β initiative. <i>Nuclear Medicine and Biology</i> , 2019, 71, 19-22.	0.6	7
36	Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1195-1204.	4.1	36

#	ARTICLE	IF	CITATIONS
37	Development of brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer's disease. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 165, 371-399.	1.7	32
38	Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D ₃ Receptor (D ₃ R) Ligand Promiscuity across Highly Conserved Aminergic G-Protein-Coupled Receptors (GPCRs). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 5132-5147.	6.4	15
39	Radiochemical Approaches to Imaging Bacterial Infections: Intracellular versus Extracellular Targets. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5808.	4.1	19
40	Synthesis and evaluation of an AZD2461 [18F]PET probe in non-human primates reveals the PARP-1 inhibitor to be non-blood-brain barrier penetrant. <i>Bioorganic Chemistry</i> , 2019, 83, 242-249.	4.1	17
41	Selectivity of probes for PET imaging of dopamine D ₃ receptors. <i>Neuroscience Letters</i> , 2019, 691, 18-25.	2.1	21
42	Open letter to journal editors on. <i>Nuclear Medicine Communications</i> , 2018, 39, 193-195.	1.1	0
43	Chalcones and Five-Membered Heterocyclic Isosteres Bind to Alpha Synuclein Fibrils in Vitro. <i>ACS Omega</i> , 2018, 3, 4486-4493.	3.5	28
44	Design, synthesis, and in vitro evaluation of quinolinyl analogues for α -synuclein aggregation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1011-1019.	2.2	13
45	Open letter to journal editors on: international consensus radiochemistry nomenclature guidelines. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2018, 315, 443-445.	1.5	0
46	Copper Loading of Preformed Nanoparticles for PET-Imaging Applications. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 3191-3199.	8.0	17
47	Open letter to journal editors on: International consensus radiochemistry nomenclature guidelines. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 402-404.	1.0	5
48	Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines. <i>Annals of Nuclear Medicine</i> , 2018, 32, 236-238.	2.2	23
49	International Consensus Radiochemistry Nomenclature Guidelines. <i>Radiochimica Acta</i> , 2018, 106, 623-625.	1.2	1
50	Rapid Cu-Catalyzed [²¹¹ At]Astatination and [¹²⁵ I]Iodination of Boronic Esters at Room Temperature. <i>Organic Letters</i> , 2018, 20, 1752-1755.	4.6	63
51	Challenges in the development of dopamine D ₂ and D ₃ -selective radiotracers for PET imaging studies. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 291-298.	1.0	23
52	Development of a Positron Emission Tomography Radiotracer for Imaging Elevated Levels of Superoxide in Neuroinflammation. <i>ACS Chemical Neuroscience</i> , 2018, 9, 578-586.	3.5	51
53	Synthesis and pharmacological evaluation of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives as sigma-2 receptor ligands. <i>European Journal of Medicinal Chemistry</i> , 2018, 147, 227-237.	5.5	20
54	Validation of gallbladder absorbed radiation dose reduction simulation: human dosimetry of [18F]fluorotripride. <i>EJNMMI Physics</i> , 2018, 5, 21.	2.7	5

#	ARTICLE	IF	CITATIONS
55	Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex. <i>Scientific Reports</i> , 2018, 8, 16845.	3.3	97
56	Dopamine D3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors. <i>Pharmacology Biochemistry and Behavior</i> , 2018, 175, 123-129.	2.9	8
57	Altering Nitrogen Heterocycles of AZD2461 Affords High Affinity Poly(ADP-ribose) Polymerase-1 Inhibitors with Decreased P-Glycoprotein Interactions. <i>ACS Omega</i> , 2018, 3, 9997-10001.	3.5	6
58	Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5367-5379.	6.4	32
59	Alpha Synuclein Fibrils Contain Multiple Binding Sites for Small Molecules. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2521-2527.	3.5	48
60	PET Imaging of Microglial Activation—Beyond Targeting TSPO. <i>Molecules</i> , 2018, 23, 607.	3.8	85
61	Analogues of Arylamide Phenylpiperazine Ligands To Investigate the Factors Influencing D3 Dopamine Receptor Bitropic Binding and Receptor Subtype Selectivity. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2972-2983.	3.5	23
62	International Consensus Radiochemistry Nomenclature Guidelines. <i>Nuklearmedizin - Nuclear Medicine</i> , 2018, 57, 40-41.	0.7	1
63	Letter to the Editor: International Consensus Radiochemistry Nomenclature Guidelines. <i>Current Radiopharmaceuticals</i> , 2018, 11, 73-75.	0.8	0
64	A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 2116-2126.	8.2	100
65	Open letter to journal editors on: international consensus radiochemistry nomenclature guidelines. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 8, 70-72.	1.0	1
66	Design and Investigation of a [¹⁸ F]-Labeled Benzamide Derivative as a High Affinity Dual Sigma Receptor Subtype Radioligand for Prostate Tumor Imaging. <i>Molecular Pharmaceutics</i> , 2017, 14, 770-780.	4.6	15
67	Quantitative PET Reporter Gene Imaging with [¹¹ C]Trimethoprim. <i>Molecular Therapy</i> , 2017, 25, 120-126.	8.2	27
68	PARP-1 Expression Quantified by [¹⁸ F]Fluorothalimide: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 9-15.	1.0	21
69	[¹⁸ F](2 <i>S</i> ,4 <i>R</i>)-4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple-Negative Breast Cancer in Response to Glutaminase Inhibition. <i>Cancer Research</i> , 2017, 77, 1476-1484.	0.9	75
70	The role of beta-arrestin2 in shaping fMRI BOLD responses to dopaminergic stimulation. <i>Psychopharmacology</i> , 2017, 234, 2019-2030.	3.1	4
71	Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2017, 486, 788-795.	2.1	9
72	A sensitive assay reveals structural requirements for α -synuclein fibril growth. <i>Journal of Biological Chemistry</i> , 2017, 292, 9034-9050.	3.4	18

#	ARTICLE	IF	CITATIONS
73	The Evolution of the Sigma-2 (σ_2) Receptor from Obscure Binding Site to Bona Fide Therapeutic Target. <i>Advances in Experimental Medicine and Biology</i> , 2017, 964, 49-61.	1.6	11
74	Current status of the development of PET radiotracers for imaging alpha synuclein aggregates in Lewy bodies and Lewy neurites. <i>Clinical and Translational Imaging</i> , 2017, 5, 3-14.	2.1	38
75	Pd-catalyzed arylation of linear and angular spirodiamine salts under aerobic conditions. <i>Tetrahedron Letters</i> , 2017, 58, 466-469.	1.4	11
76	Consensus nomenclature rules for radiopharmaceutical chemistry "Setting the record straight. <i>Nuclear Medicine and Biology</i> , 2017, 55, v-xi.	0.6	162
77	Bacterial infection imaging with [18 F]fluoropropyl-trimethoprim. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8372-8377.	7.1	111
78	Small Molecule Receptor Ligands for PET Studies of the Central Nervous System"Focus on G Protein Coupled Receptors. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 524-535.	4.6	10
79	Inflammation and DNA damage: Probing pathways to cancer and neurodegeneration. <i>Drug Discovery Today: Technologies</i> , 2017, 25, 37-43.	4.0	4
80	Highly Selective Dopamine D ₃ Receptor Antagonists with Arylated Diazaspiro Alkane Cores. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9905-9910.	6.4	27
81	The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 14.	8.6	8
82	PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies. <i>Radiology</i> , 2017, 282, 453-463.	7.3	57
83	Automation of the Radiosynthesis of Six Different 18 F-labeled radiotracers on the AllinOne. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2017, 1, 15.	3.9	30
84	A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. <i>JCI Insight</i> , 2017, 2, e89760.	5.0	55
85	Molecular Probes for Imaging the Sigma-2 Receptor: In Vitro and In Vivo Imaging Studies. <i>Handbook of Experimental Pharmacology</i> , 2016, 244, 309-330.	1.8	17
86	The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic. <i>Nuclear Medicine and Biology</i> , 2016, 43, 35-41.	0.6	18
87	4-arylpiperidines and 4-(\pm -hydroxyphenyl)piperidines as selective sigma-1 receptor ligands: synthesis, preliminary pharmacological evaluation and computational studies. <i>Chemistry Central Journal</i> , 2016, 10, 53.	2.6	2
88	4-(((4-Iodophenyl)methyl)-4 <i>H</i> -1,2,4-triazol-4-ylamino)-benzonitrile: A Potential Imaging Agent for Aromatase. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9370-9380.	6.4	8
89	Comparative evaluation of 4 and 6-carbon spacer conformationally flexible tetrahydroisoquinoliny benzamide analogues for imaging the sigma-2 receptor status of solid tumors. <i>Nuclear Medicine and Biology</i> , 2016, 43, 721-731.	0.6	13
90	Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo. <i>Nuclear Medicine and Biology</i> , 2016, 43, 752-758.	0.6	25

#	ARTICLE	IF	CITATIONS
91	The effect of the sigma-1 receptor selective compound LS-1-137 on the DOI-induced head twitch response in mice. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 148, 136-144.	2.9	5
92	A systematic exploration of the effects of flexibility and basicity on sigma (σ) receptor binding in a series of substituted diamines. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 9388-9405.	2.8	2
93	Pd-Catalyzed Synthesis of Piperazine Scaffolds Under Aerobic and Solvent-Free Conditions. <i>Organic Letters</i> , 2016, 18, 5272-5275.	4.6	35
94	A Radiotracer Strategy to Quantify PARP-1 Expression <i>In Vivo</i> Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy. <i>Cancer Research</i> , 2016, 76, 4516-4524.	0.9	77
95	Novel Strategies for Breast Cancer Imaging: New Imaging Agents to Guide Treatment. <i>Journal of Nuclear Medicine</i> , 2016, 57, 69S-74S.	5.0	10
96	The PGRMC1 Protein Level Correlates with the Binding Activity of a Sigma-2 Fluorescent Probe (SW120) in Rat Brain Cells. <i>Molecular Imaging and Biology</i> , 2016, 18, 172-179.	2.6	21
97	Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. <i>Oncotarget</i> , 2016, 7, 33529-33541.	1.8	21
98	[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 6, 94-101.	1.0	30
99	PET imaging of in vivo caspase-3/7 activity following myocardial ischemia-reperfusion injury with the radiolabeled isatin sulfonamide analogue [(18)F]WC-4-116. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 6, 110-9.	1.0	11
100	Absorbed radiation dosimetry of the D-specific PET radioligand [F]FluorTriopride estimated using rodent and nonhuman primate. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 6, 301-309.	1.0	6
101	Improved Automated Radiosynthesis of [11C]PBR28. <i>Scientia Pharmaceutica</i> , 2015, 83, 413-427.	2.0	7
102	The effects of sigma (σ) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice. <i>British Journal of Pharmacology</i> , 2015, 172, 2519-2531.	5.4	37
103	Pharmacological modulation of abnormal involuntary DOI-induced head twitch response movements in male DBA/2 mice: II. Effects of D3 dopamine receptor selective compounds. <i>Neuropharmacology</i> , 2015, 93, 179-190.	4.1	7
104	Synthesis and evaluation of tetrahydroindazole derivatives as sigma-2 receptor ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 1463-1471.	3.0	15
105	Facile purification and click labeling with 2-[18F]fluoroethyl azide using solid phase extraction cartridges. <i>Tetrahedron Letters</i> , 2015, 56, 952-954.	1.4	17
106	Synthesis, pharmacological evaluation and molecular modeling studies of triazole containing dopamine D3 receptor ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 519-523.	2.2	15
107	Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for β -Synuclein Fibrils. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6002-6017.	6.4	92
108	Sigma-2 receptor binding is decreased in female, but not male, APP/PS1 mice. <i>Biochemical and Biophysical Research Communications</i> , 2015, 460, 439-445.	2.1	16

#	ARTICLE	IF	CITATIONS
109	Imaging Caspase-3 Activation as a Marker of Apoptosis-Targeted Treatment Response in Cancer. <i>Molecular Imaging and Biology</i> , 2015, 17, 384-393.	2.6	49
110	Imaging Pulmonary Inducible Nitric Oxide Synthase Expression with PET. <i>Journal of Nuclear Medicine</i> , 2015, 56, 76-81.	5.0	41
111	Novel indole-based sigma-2 receptor ligands: synthesis, structure-activity relationship and antiproliferative activity. <i>MedChemComm</i> , 2015, 6, 1093-1103.	3.4	15
112	The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer. <i>Biochemical and Biophysical Research Communications</i> , 2015, 467, 1070-1075.	2.1	17
113	Alzheimer's Therapeutics Targeting Amyloid Beta 1-42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity. <i>PLoS ONE</i> , 2014, 9, e111899.	2.5	151
114	Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging β -Synuclein. <i>Applied Sciences (Switzerland)</i> , 2014, 4, 66-78.	2.5	51
115	Characterization of [³ H]LS-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand. <i>Journal of Neurochemistry</i> , 2014, 131, 418-431.	3.9	17
116	Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer. <i>Molecular Cancer</i> , 2014, 13, 50.	19.2	24
117	Synthesis, [18F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 1700-1707.	3.0	64
118	Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. <i>Molecular Oncology</i> , 2014, 8, 956-967.	4.6	38
119	Using SV119-Gold Nanocage Conjugates to Eradicate Cancer Stem Cells Through a Combination of Photothermal and Chemo Therapies. <i>Advanced Healthcare Materials</i> , 2014, 3, 1283-1291.	7.6	69
120	Pharmacological modulation of abnormal involuntary DOI-induced head twitch response in male DBA/2J mice: I. Effects of D2/D3 and D2 dopamine receptor selective compounds. <i>Neuropharmacology</i> , 2014, 83, 18-27.	4.1	15
121	Epigenetic Priming of Memory Updating during Reconsolidation to Attenuate Remote Fear Memories. <i>Cell</i> , 2014, 156, 261-276.	28.9	318
122	Development of a PET radiotracer for non-invasive imaging of the reactive oxygen species, superoxide, in vivo. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 4421-4431.	2.8	74
123	Synthesis and Structure-Activity Relationship Studies of Conformationally Flexible Tetrahydroisoquinoliny Triazole Carboxamide and Triazole Substituted Benzamide Analogues as β -2 Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4239-4251.	6.4	33
124	New Targets for the Development of PET Tracers for Imaging Neurodegeneration in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1221-1224.	5.0	26
125	Functional assays to define agonists and antagonists of the sigma-2 receptor. <i>Analytical Biochemistry</i> , 2014, 448, 68-74.	2.4	35
126	Automated radiochemical synthesis and biodistribution of [11C]- β -acetylmethadol ([11C]LAAM). <i>Applied Radiation and Isotopes</i> , 2014, 91, 135-140.	1.5	4

#	ARTICLE	IF	CITATIONS
127	Synthesis and in vitro pharmacological evaluation of indolyl carboxylic amide analogues as D3 dopamine receptor selective ligands. <i>MedChemComm</i> , 2013, 4, 1283.	3.4	1
128	Positron emission tomography imaging of dopamine D2 receptors using a highly selective radiolabeled D2 receptor partial agonist. <i>NeuroImage</i> , 2013, 71, 168-174.	4.2	10
129	Regulation of dopamine presynaptic markers and receptors in the striatum of DJ-1 and Pink1 knockout rats. <i>Neuroscience Letters</i> , 2013, 557, 123-128.	2.1	25
130	Evaluation of N-phenyl homopiperazine analogs as potential dopamine D3 receptor selective ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 2988-2998.	3.0	13
131	The β_2 Receptor: A Novel Protein for the Imaging and Treatment of Cancer. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7137-7160.	6.4	131
132	The Effect of SV 293, a D2 Dopamine Receptor-Selective Antagonist, on D2 Receptor-Mediated GIRK Channel Activation and Adenylyl Cyclase Inhibition. <i>Pharmacology</i> , 2013, 92, 84-89.	2.2	7
133	Reduction of Cocaine Self-Administration and D3 Receptor-Mediated Behavior by Two Novel Dopamine D3 Receptor-Selective Partial Agonists, OS-3-106 and WW-III-55. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 347, 410-423.	2.5	24
134	^{18}F -AFETP, ^{18}F -FET, and ^{18}F -FDG Imaging of Mouse DBT Gliomas. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1120-1126.	5.0	28
135	Antagonism of Inhibitor of Apoptosis Proteins Increases Bone Metastasis via Unexpected Osteoclast Activation. <i>Cancer Discovery</i> , 2013, 3, 212-223.	9.4	39
136	Assessment of Cellular Proliferation in Tumors by PET Using ^{18}F -ISO-1. <i>Journal of Nuclear Medicine</i> , 2013, 54, 350-357.	5.0	76
137	Fos expression in response to dopamine D3-preferring phenylpiperazine drugs given with and without cocaine. <i>Synapse</i> , 2013, 67, 847-855.	1.2	1
138	Binding of the Radioligand SIL23 to α -Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasibility and Screening Approaches for Developing a Parkinson Disease Imaging Agent. <i>PLoS ONE</i> , 2013, 8, e55031.	2.5	97
139	Quantitative Receptor-Based Imaging of Tumor Proliferation with the Sigma-2 Ligand [18F]ISO-1. <i>PLoS ONE</i> , 2013, 8, e74188.	2.5	41
140	Development of ^{18}F -Labeled PET Probes for Imaging Cell Proliferation. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 892-908.	2.1	10
141	Feasibility and Dosimetry Studies for ^{18}F -NOS as a Potential PET Radiopharmaceutical for Inducible Nitric Oxide Synthase in Humans. <i>Journal of Nuclear Medicine</i> , 2012, 53, 994-1001.	5.0	33
142	Use of Multifunctional Sigma-2 Receptor Ligand Conjugates to Trigger Cancer-Selective Cell Death Signaling. <i>Cancer Research</i> , 2012, 72, 201-209.	0.9	41
143	SV119-gold nanocage conjugates: a new platform for targeting cancer cells via sigma-2 receptors. <i>Nanoscale</i> , 2012, 4, 421-424.	5.6	45
144	Pathologic Accumulation of α -Synuclein and $\text{A}\beta$ in Parkinson Disease Patients With Dementia. <i>Archives of Neurology</i> , 2012, 69, 1326.	4.5	173

#	ARTICLE	IF	CITATIONS
145	Comparison of the Binding and Functional Properties of Two Structurally Different D2 Dopamine Receptor Subtype Selective Compounds. <i>ACS Chemical Neuroscience</i> , 2012, 3, 1050-1062.	3.5	25
146	Synthesis, radiolabeling and initial in vivo evaluation of [11C]KSM-01 for imaging PPAR- α receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6233-6236.	2.2	12
147	Synthesis and evaluation of 18F-labeled PPAR- α antagonists. <i>Nuclear Medicine and Biology</i> , 2012, 39, 77-87.	0.6	12
148	Radiolabeled isatin binding to caspase-3 activation induced by anti-Fas antibody. <i>Nuclear Medicine and Biology</i> , 2012, 39, 137-144.	0.6	22
149	Synthesis and in vitro evaluation of α -synuclein ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 4625-4634.	3.0	51
150	Exploration of ring size in a series of cyclic vicinal diamines with α 1 receptor affinity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5493-5497.	2.2	11
151	Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands. <i>Surgery</i> , 2012, 152, S152-S156.	1.9	28
152	Highly efficient click labeling using 2-[18F]fluoroethyl azide and synthesis of an 18FN-hydroxysuccinimide ester as conjugation agent. <i>Nuclear Medicine and Biology</i> , 2012, 39, 1175-1181.	0.6	20
153	Lysosomal Membrane Permeabilization is an Early Event in Sigma-2 Receptor Ligand Mediated Cell Death in Pancreatic Cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 41.	8.6	64
154	Sigma-2 Receptor as Potential Indicator of Stem Cell Differentiation. <i>Molecular Imaging and Biology</i> , 2012, 14, 325-335.	2.6	16
155	Neuroprotective effects of high affinity sigma 1 receptor selective compounds. <i>Brain Research</i> , 2012, 1441, 17-26.	2.2	30
156	No Differential Regulation of Dopamine Transporter (DAT) and Vesicular Monoamine Transporter 2 (VMAT2) Binding in a Primate Model of Parkinson Disease. <i>PLoS ONE</i> , 2012, 7, e31439.	2.5	28
157	Dopamine D1, D2, D3 Receptors, Vesicular Monoamine Transporter Type-2 (VMAT2) and Dopamine Transporter (DAT) Densities in Aged Human Brain. <i>PLoS ONE</i> , 2012, 7, e49483.	2.5	62
158	The antipsychotic aripiprazole is a non-competitive antagonist of dopamine-stimulated D2 receptor interactions with α -arrestin-2. <i>FASEB Journal</i> , 2012, 26, 665.2.	0.5	0
159	Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. <i>Nature Communications</i> , 2011, 2, 380.	12.8	277
160	Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain. <i>Nuclear Medicine and Biology</i> , 2011, 38, 725-739.	0.6	14
161	Characterization and Evaluation of Two Novel Fluorescent Sigma-2 Receptor Ligands as Proliferation Probes. <i>Molecular Imaging</i> , 2011, 10, 7290.2011.00009.	1.4	37
162	Sleep deprivation differentially affects dopamine receptor subtypes in mouse striatum. <i>NeuroReport</i> , 2011, 22, 489-493.	1.2	36

#	ARTICLE	IF	CITATIONS
163	Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 3986-3995.	5.5	8
164	PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. <i>Experimental Neurology</i> , 2011, 232, 333-338.	4.1	35
165	N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (σ) receptor ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 5289-5292.	2.2	21
166	Synthesis and Pharmacological Evaluation of Fluorine-Containing D ₃ Dopamine Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1555-1564.	6.4	42
167	Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy. <i>Molecular Neurodegeneration</i> , 2011, 6, 86.	10.8	47
168	Endogenous dopamine (DA) competes with the binding of a radiolabeled D ₃ receptor partial agonist in vivo: A positron emission tomography study. <i>Synapse</i> , 2011, 65, 724-732.	1.2	39
169	Decreased striatal dopamine receptor binding in primary focal dystonia: A D2 or D3 defect?. <i>Movement Disorders</i> , 2011, 26, 100-106.	3.9	44
170	Radiosynthesis and in vivo evaluation of [¹¹ C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 1666-1673.	3.0	55
171	Synthesis and evaluation of isatin analogs as caspase-3 inhibitors: Introduction of a hydrophilic group increases potency in a whole cell assay. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2192-2197.	2.2	35
172	Automated radiosynthesis of [¹¹ C]morphine for clinical investigation. <i>Applied Radiation and Isotopes</i> , 2011, 69, 431-435.	1.5	2
173	Synthesis and characterization of selective dopamine D2 receptor ligands using aripiprazole as the lead compound. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 3502-3511.	3.0	43
174	Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes. <i>Molecular Imaging</i> , 2011, 10, 420-33.	1.4	22
175	Radiochemical Synthesis, Rodent Biodistribution and Tumor Uptake, and Dosimetry Calculations of [¹¹ C] Methylated LY2181308. <i>Molecular Imaging and Biology</i> , 2010, 12, 608-615.	2.6	9
176	Evaluation of 5-ethynyl-2-deoxyuridine staining as a sensitive and reliable method for studying cell proliferation in the adult nervous system. <i>Brain Research</i> , 2010, 1319, 21-32.	2.2	172
177	Radiosynthesis and biological evaluation of a promising σ -receptor ligand radiolabeled with fluorine-18 or iodine-125 as a PET/SPECT probe for imaging breast cancer. <i>Applied Radiation and Isotopes</i> , 2010, 68, 2268-2273.	1.5	28
178	Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5291-5300.	3.0	20
179	[³ H]4-(dimethylamino)-N-(4-(2-methoxyphenyl)piperazin-1-yl)butylbenzamide: A selective radioligand for dopamine D ₃ receptors. II. Quantitative analysis of dopamine D ₃ and D ₂ receptor density ratio in the caudate-putamen. <i>Synapse</i> , 2010, 64, 449-459.	1.2	34
180	Click Synthesis and Biologic Evaluation of (S)- and (R)-2-Amino-3-[1-(2- ¹⁸ F)Fluoroethyl]-1H-[1,2,3]Triazol-4-yl]Propanoic Acid for Brain Tumor Imaging with Positron Emission Tomography. <i>Molecular Imaging</i> , 2010, 9, 7290.2010.00025.	1.4	27

#	ARTICLE	IF	CITATIONS
181	The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. <i>Molecular Cancer</i> , 2010, 9, 298.	19.2	70
182	Synthesis and Evaluation of 15-(4-(2-[¹⁸ F]Fluoroethoxy)phenyl)pentadecanoic Acid: A Potential PET Tracer for Studying Myocardial Fatty Acid Metabolism. <i>Bioconjugate Chemistry</i> , 2010, 21, 2313-2319.	3.6	19
183	Synthesis and <i>In Vitro</i> Biological Evaluation of Carbonyl Group-Containing Inhibitors of Vesicular Acetylcholine Transporter. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 2825-2835.	6.4	25
184	Subtype Selectivity of Dopamine Receptor Ligands: Insights from Structure and Ligand-Based Methods. <i>Journal of Chemical Information and Modeling</i> , 2010, 50, 1970-1985.	5.4	64
185	Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. <i>Nuclear Medicine and Biology</i> , 2010, 37, 509-516.	0.6	48
186	Challenges for Developing PET Tracers: Isotopes, Chemistry, and Regulatory Aspects. <i>PET Clinics</i> , 2010, 5, 131-153.	3.0	12
187	Spatial correlation between brain aerobic glycolysis and amyloid- β^2 (A β^2) deposition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 17763-17767.	7.1	338
188	Using prepulse inhibition to detect functional D3 receptor antagonism: Effects of WC10 and WC44. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 93, 141-147.	2.9	16
189	Cerebrospinal fluid tau and ptau ₁₈₁ increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2009, 1, 371-380.	6.9	315
190	[³ H]4-(Dimethylamino)N-(4-(2-methoxyphenyl)piperazin-1-yl)butyl]benzamide, a selective radioligand for dopamine D ₃ receptors. I. In vitro characterization. <i>Synapse</i> , 2009, 63, 717-728.	1.2	27
191	New N-substituted 9-azabicyclo[3.3.1]nonan-3-yl phenylcarbamate analogs as α_2 receptor ligands: Synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 1222-1231.	3.0	40
192	Evaluation of D2 and D3 dopamine receptor selective compounds on l-dopa-dependent abnormal involuntary movements in rats. <i>Neuropharmacology</i> , 2009, 56, 956-969.	4.1	51
193	Comparison of radiolabeled isatin analogs for imaging apoptosis with positron emission tomography. <i>Nuclear Medicine and Biology</i> , 2009, 36, 651-658.	0.6	40
194	Synthesis and in Vitro Evaluation of Sulfonamide Isatin Michael Acceptors as Small Molecule Inhibitors of Caspase-6. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2188-2191.	6.4	46
195	Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma. <i>Journal of Translational Medicine</i> , 2009, 7, 24.	4.4	55
196	[18F]- and [11C]-Labeled N-benzyl-isatin sulfonamide analogues as PET tracers for Apoptosis: synthesis, radiolabeling mechanism, and in vivo imaging study of apoptosis in Fas-treated mice using [11C]WC-98. <i>Organic and Biomolecular Chemistry</i> , 2009, 7, 1337.	2.8	69
197	PET Radiotracers for Imaging the Proliferative Status of Solid Tumors. <i>PET Clinics</i> , 2009, 4, 1-15.	3.0	23
198	Docking and 3D-QSAR Studies on Isatin Sulfonamide Analogues as Caspase-3 Inhibitors. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 1963-1973.	5.4	40

#	ARTICLE	IF	CITATIONS
199	Design and Synthesis of 2-Amino-4-methylpyridine Analogues as Inhibitors for Inducible Nitric Oxide Synthase and in Vivo Evaluation of [¹⁸ F]6-(2-Fluoropropyl)-4-methyl-pyridin-2-amine as a Potential PET Tracer for Inducible Nitric Oxide Synthase. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2443-2453.	6.4	48
200	Synthesis and in Vitro and in Vivo Evaluation of ¹⁸ F-Labeled Positron Emission Tomography (PET) Ligands for Imaging the Vesicular Acetylcholine Transporter. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1358-1369.	6.4	48
201	Preface. <i>PET Clinics</i> , 2009, 4, ix-x.	3.0	0
202	Targeted delivery to tumors in vivo with sigma ₂ ligands. <i>FASEB Journal</i> , 2008, 22, 651.8.	0.5	1
203	Subcellular Localization of Sigma-2 Receptors in Breast Cancer Cells Using Two-Photon and Confocal Microscopy. <i>Cancer Research</i> , 2007, 67, 6708-6716.	0.9	112
204	IN VIVO IMAGING IN A MURINE MODEL OF GLIOBLASTOMA. <i>Neurosurgery</i> , 2007, 60, 360-371.	1.1	37
205	Isatin Sulfonamide Analogs Containing a Michael Addition Acceptor: A New Class of Caspase 3/7 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3751-3755.	6.4	67
206	Fluorine-18-Labeled Benzamide Analogues for Imaging the β_2 Receptor Status of Solid Tumors with Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3194-3204.	6.4	102
207	Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. <i>Molecular Cancer</i> , 2007, 6, 48.	19.2	118
208	Imaging the proliferative status of tumors with PET. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2007, 50, 366-369.	1.0	8
209	Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker. <i>Nuclear Medicine and Biology</i> , 2006, 33, 203-209.	0.6	45
210	PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. <i>Nature Neuroscience</i> , 2006, 9, 1050-1056.	14.8	412
211	Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3-yl carbamate analogs as β_2 receptor ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 6988-6997.	3.0	45
212	Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5041-5046.	2.2	116
213	Synthesis and characterization of selective dopamine D2 receptor antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 815-825.	3.0	36
214	Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A β_{42} in humans. <i>Annals of Neurology</i> , 2006, 59, 512-519.	5.3	1,190
215	Synthesis and in vivo evaluation of 2 high-affinity ⁷⁶ Br-labeled sigma2-receptor ligands. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1041-8.	5.0	37
216	Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 77-87.	3.0	99

#	ARTICLE	IF	CITATIONS
217	[3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: A novel sigma-2 receptor probe. <i>European Journal of Pharmacology</i> , 2005, 525, 8-17.	3.5	60
218	N-[18F]4- ² -fluorobenzylpiperidin-4-yl-(2-fluorophenyl) acetamide ([18F]FBFPA): A potential fluorine-18 labeled PET radiotracer for imaging sigma-1 receptors in the CNS. <i>Synapse</i> , 2005, 58, 267-274.	1.2	17
219	Altered Neuronal Mitochondrial Coenzyme A Synthesis in Neurodegeneration with Brain Iron Accumulation Caused by Abnormal Processing, Stability, and Catalytic Activity of Mutant Pantothenate Kinase 2. <i>Journal of Neuroscience</i> , 2005, 25, 689-698.	3.6	141
220	Synthesis and in vivo evaluation of [11C]PJ34, a potential radiotracer for imaging the role of PARP-1 in necrosis. <i>Nuclear Medicine and Biology</i> , 2005, 32, 437-443.	0.6	45
221	Carbon-11 labeled β 2 receptor ligands for imaging breast cancer. <i>Nuclear Medicine and Biology</i> , 2005, 32, 423-430.	0.6	67
222	N-Benzylisatin Sulfonamide Analogues as Potent Caspase-3 Inhibitors: Synthesis, in Vitro Activity, and Molecular Modeling Studies. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7637-7647.	6.4	92
223	Conformationally-flexible benzamide analogues as dopamine D3 and β 2 receptor ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 195-202.	2.2	90
224	Fibrillization of β -synuclein and tau in familial Parkinson's disease caused by the A53T β -synuclein mutation. <i>Experimental Neurology</i> , 2004, 187, 279-288.	4.1	151
225	Synthesis of 2-(5-Bromo-2,3-dimethoxyphenyl)-5-(aminomethyl)-1H-pyrrole analogues and their binding affinities for dopamine D2, D3, and D4 receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 225-233.	3.0	27
226	Progress in Developing D3 Dopamine Receptor Ligands as Potential Therapeutic Agents for Neurological and Neuropsychiatric Disorders. <i>Current Pharmaceutical Design</i> , 2003, 9, 643-671.	1.9	85
227	Cocaine- and food-maintained responding under a multiple schedule in rhesus monkeys: environmental context and the effects of a dopamine antagonist. <i>Psychopharmacology</i> , 2002, 163, 292-301.	3.1	11
228	Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration. <i>Nature Neuroscience</i> , 2002, 5, 169-174.	14.8	645
229	Morphine-induced spinal cholinergic activation: in vivo imaging with positron emission tomography. <i>Pain</i> , 2001, 91, 139-145.	4.2	18
230	Development of a Tc-99m labeled sigma-2 receptor-specific ligand as a potential breast tumor imaging agent. <i>Nuclear Medicine and Biology</i> , 2001, 28, 657-666.	0.6	71
231	Synthesis and Structure-Activity Relationships of N-(1-Benzylpiperidin-4-yl)arylacetamide Analogues as Potent β 1 Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 4404-4415.	6.4	21
232	Synthesis of 2-(2,3-dimethoxyphenyl)-4-(aminomethyl)imidazole analogues and their binding affinities for dopamine D2 and D3 receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2001, 9, 3113-3122.	3.0	17
233	Preparation of a technetium-99m SPECT agent for imaging the sigma-2 receptor status of solid tumors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001, 44, 899-908.	1.0	8
234	Cholinergic activity of aged rhesus monkeys revealed by positron emission tomography. <i>Synapse</i> , 2001, 39, 95-100.	1.2	30

#	ARTICLE	IF	CITATIONS
235	Synthesis and Structure-Activity Relationships of Naphthamides as Dopamine D3 Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 1815-1826.	6.4	24
236	Lewy Body Pathology in Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2001, 17, 225-232.	2.3	138
237	Fluorine-18-labeled tropane analogs for PET imaging studies of the dopamine transporter. <i>Synapse</i> , 2000, 37, 109-117.	1.2	23
238	Characterization of 125I-IABN, a novel azabicyclononane benzamide selective for D2-like dopamine receptors. <i>Synapse</i> , 2000, 38, 438-449.	1.2	48
239	Hydroxylated Decahydroquinolines as Ligands for the Vesicular Acetylcholine Transporter: Synthesis and Biological Evaluation. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 2862-2869.	6.4	18
240	PET Imaging of Dopamine D2 Receptors with [18F]Fluoroclebopride in Monkeys Effects of Isoflurane- and Ketamine-Induced Anesthesia. <i>Neuropsychopharmacology</i> , 1999, 21, 589-596.	5.4	28
241	Dopamine D2/D3 receptors modulate cocaine's reinforcing and discriminative stimulus effects in rhesus monkeys. <i>Drug and Alcohol Dependence</i> , 1999, 54, 97-110.	3.2	60
242	The analgesic tropane analogue (±)-SM 21 has a high affinity for μ 2 receptors. <i>Life Sciences</i> , 1999, 64, PL131-PL137.	4.3	36
243	In Vivo Imaging of the Spinal Cord Cholinergic System with PET. <i>Journal of Computer Assisted Tomography</i> , 1999, 23, 25-33.	0.9	5
244	Effect of social status on striatal dopamine D2 receptor binding characteristics in cynomolgus monkeys assessed with positron emission tomography. <i>Synapse</i> , 1998, 29, 80-83.	1.2	185
245	Synthesis and Quantitative Structure-Activity Relationships of N-(1-Benzylpiperidin-4-yl)phenylacetamides and Related Analogues as Potent and Selective μ 1 Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 2361-2370.	6.4	36
246	N-Hydroxyalkyl Derivatives of 3 β -Phenyltropane and 1-Methylspiro[1H-indoline-3,4-piperidine]: Vesamicol Analogues with Affinity for Monoamine Transporters. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 3905-3914.	6.4	28
247	Social Stress, Depression, and Brain Dopamine in Female Cynomolgus Monkeys. <i>Annals of the New York Academy of Sciences</i> , 1997, 807, 574-577.	3.8	57
248	Use of Positron Emission Tomography to Study the Dynamics of Psychostimulant-Induced Dopamine Release. <i>Pharmacology Biochemistry and Behavior</i> , 1997, 57, 477-486.	2.9	46
249	Imaging of cholinergic terminals using the radiotracer [18F](+)-4-fluorobenzyltrozamicol: In vitro binding studies and positron emission tomography studies in nonhuman primates. , 1997, 25, 368-380.		45
250	Comparison of two fluorine-18 labeled benzamide derivatives that bind reversibly to dopamine D2 receptors: In vitro binding studies and positron emission tomography. , 1996, 24, 322-333.		28
251	Pet imaging studies of dopamine D2 receptors: Comparison of [18F]N-Methylspiperone; and the benzamide analogues [18F]MABN and [18F]MBP in baboon brain. <i>Synapse</i> , 1995, 19, 177-187.	1.2	11
252	lbgaine possesses a selective affinity for μ 2 receptors. <i>Life Sciences</i> , 1995, 57, PL57-PL62.	4.3	130

#	ARTICLE	IF	CITATIONS
253	Vesamicol analogues as sigma ligands. <i>Biochemical Pharmacology</i> , 1995, 49, 791-797.	4.4	63
254	Fluorine-18 labeled benzamides for studying the dopamine D2 receptor with positron emission tomography. <i>Journal of Medicinal Chemistry</i> , 1993, 36, 3707-3720.	6.4	51
255	The use of [18F]4-fluorobenzyl iodide (FBI) in PET radiotracer synthesis: Model alkylation studies and its application in the design of dopamine D1 and D2 receptor-based imaging agents. <i>Nuclear Medicine and Biology</i> , 1993, 20, 777-794.	0.6	47
256	Synthesis and in vivo evaluation of [18F]-N-(p-Nitrobenzyl)piperone ([18F]PNBS) in rats. <i>Nuclear Medicine and Biology</i> , 1993, 20, 269-278.	0.6	6
257	Effect of N-alkylation on the affinities of analogs of spiperone for dopamine D2 and serotonin 5-HT2 receptors. <i>Journal of Medicinal Chemistry</i> , 1992, 35, 423-430.	6.4	28
258	Antibodies with high affinity for spiroperidol ¹¹ . cross reactivity with iodobenzamide and domperidone. <i>Molecular Immunology</i> , 1990, 27, 667-677.	2.2	1
259	Dopamine D-2 receptor imaging radiopharmaceuticals: synthesis, radiolabeling and in vitro binding of (R)-(+)- and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide. <i>Journal of Medicinal Chemistry</i> , 1988, 31, 1039-1043.	6.4	83